Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA...

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• The TALAPRO-1 study (NCT03148795) investigated talazoparib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
• This analysis focuses on the safety profile of talazoparib in this patient population.

Purpose of the Study:

• To detail the safety profile of talazoparib in men with mCRPC.
• To evaluate adverse events (AEs), including incidence, severity, timing, duration, and management strategies.

Main Methods:

• Men received oral talazoparib (1 mg/day, or 0.75 mg/day with moderate renal impairment) until disease progression, toxicity, or other specified reasons.
• Adverse events were systematically monitored, including laboratory values and vital signs.

Main Results:

• 95.3% of patients experienced treatment-emergent adverse events (TEAEs), with anemia (48.8%), nausea (33.1%), decreased appetite (28.3%), and asthenia (23.6%) being most common.
• Hematologic TEAEs were generally short-lived, and no treatment-related grade 5 TEAEs or deaths occurred. BRCA status did not significantly impact safety.
• Permanent treatment discontinuation due to TEAEs was low (11.8%), with only 3 patients discontinuing due to hematologic TEAEs.

Conclusions:

• Common TEAEs associated with talazoparib are manageable with dose modifications and supportive care.
• The manageable safety profile, coupled with demonstrated efficacy, supports the continued evaluation of talazoparib in mCRPC.